search
Back to results

Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in VIH Infection.

Primary Purpose

HIV -1 Infection

Status
Unknown status
Phase
Phase 2
Locations
Spain
Study Type
Interventional
Intervention
Probiotic.
Placebo
Sponsored by
Parc de Salut Mar
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV -1 Infection focused on measuring Probiotic, HIV, Microbial translocation, inflammation, microbiota composition

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with chronic HIV infection and viral load undetectable > two years with stable ART CD4> 400 cells / ml.
  • Patients with chronic HIV infection and viral load undetectable> two years with stable ART CD4 <350 cells / ml.
  • Inform consent signed.
  • Aged between 18- No limit.

Exclusion Criteria:

  • Patients who receive or have received in the past 6 months food supplements containing probiotics.
  • Patients who have received antibiotic treatment in the last two months
  • Patients who are poor presupposes adherence to dietary supplements.
  • Patients who have changed the TAR in the last three months.

Sites / Locations

  • Hospital del Mar

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Probiotic

Placebo

Arm Description

A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.

No active substance is given.

Outcomes

Primary Outcome Measures

To evaluate microbial translocation-Binding lipopolysaccharide Protein (LBP).
To evaluate Gut microbiota composition.
Change in gut microbiota (454 pyrosequencing of fecal samples).

Secondary Outcome Measures

To evaluate Markers of immune activity: soluble CD14 (sCD14), interferon gamma (IFN-Υ), tumor necrosis factor (TNF), IL-6, Reactive C protein, D -dimer, fibrinogen.
Analyse parameters that determine the immune status: CD4 + lymphocyte count, CD 8 + and HIV viral load.

Full Information

First Posted
July 22, 2013
Last Updated
November 11, 2016
Sponsor
Parc de Salut Mar
search

1. Study Identification

Unique Protocol Identification Number
NCT01908049
Brief Title
Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in VIH Infection.
Official Title
Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in VIH Infection.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Unknown status
Study Start Date
August 2012 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
March 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Parc de Salut Mar

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Objectives: MAIN: To evaluate the parameters of microbial translocation after treatment with probiotics (Saccharomyces boulardii) in HIV+ patients and its role on immune reconstitution and the changes in gut microbiota composition. SECONDARY OBJECTIVES: 1) To analyze the progress of immune activity markers after the administration of probiotics. 2) To determine the improvement of CD4+ lymphocytes and HIV viral load in patients after taking probiotics. Methods: Design: A prospective randomized open controlled double-blinded trial, to be performed at a tertiary care hospital in Barcelona. Subjects: Chronic HIV infected patients. Sample size: 44 cases. They´ll be divided in 2 groups: (1) Patients with CD4 +> 400 cells / ml and undetectable viral load for more than two years (22 cases) and (2) Patients with immunodiscordancy, defined as patients with CD4 + T cells lower than 350 cells / ml despite 4-7 years of effective antiretroviral therapy. (22 cases). Intervention: Patients were randomized in 2 subgroups: (A) they´ll receive daily oral supplementation with S. boulardii for 3 months and (B) they ´ll receive placebo. Variables: bacterial lipopolisaccharide levels measured by the Lipid-Binding protein (LBP), parameters of immune activation in plasma (soluble CD14, IFN-Υ, TNF-Alpha, IL (interleukine)-2, IL-5, IL-6, IL-12)and gut microbiota composition prior to the use of probiotics (baseline), at 3 and 6 months. Immunological and clinical data. Outcome measures: quantification of bacterial translocation levels, markers of activity and immune recovery. Analysis: Comparison of variables before and after the intervention. The analysis will be performed by biological and immunological effectiveness.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV -1 Infection
Keywords
Probiotic, HIV, Microbial translocation, inflammation, microbiota composition

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Probiotic
Arm Type
Experimental
Arm Description
A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
No active substance is given.
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
To evaluate microbial translocation-Binding lipopolysaccharide Protein (LBP).
Time Frame
From randomisation to 6 months.
Title
To evaluate Gut microbiota composition.
Description
Change in gut microbiota (454 pyrosequencing of fecal samples).
Time Frame
From randomisation to 6 months.
Secondary Outcome Measure Information:
Title
To evaluate Markers of immune activity: soluble CD14 (sCD14), interferon gamma (IFN-Υ), tumor necrosis factor (TNF), IL-6, Reactive C protein, D -dimer, fibrinogen.
Time Frame
From randomisation to 6 months.
Title
Analyse parameters that determine the immune status: CD4 + lymphocyte count, CD 8 + and HIV viral load.
Time Frame
From randomisation to 6 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with chronic HIV infection and viral load undetectable > two years with stable ART CD4> 400 cells / ml. Patients with chronic HIV infection and viral load undetectable> two years with stable ART CD4 <350 cells / ml. Inform consent signed. Aged between 18- No limit. Exclusion Criteria: Patients who receive or have received in the past 6 months food supplements containing probiotics. Patients who have received antibiotic treatment in the last two months Patients who are poor presupposes adherence to dietary supplements. Patients who have changed the TAR in the last three months.
Facility Information:
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
25469528
Citation
Villar-Garcia J, Hernandez JJ, Guerri-Fernandez R, Gonzalez A, Lerma E, Guelar A, Saenz D, Sorli L, Montero M, Horcajada JP, Knobel Freud H. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):256-63. doi: 10.1097/QAI.0000000000000468.
Results Reference
derived

Learn more about this trial

Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in VIH Infection.

We'll reach out to this number within 24 hrs